Vaccines
It’s not the COVID-19 vaccine that will get you. The real cause for concern is the virus, and it lies in the fact that both male and female reproductive organs contain cell receptors the virus targets.
Population demographics appear to play a crucial role in the development of immunity via vaccination.
Teamed up with pharma giant GlaxoSmithKline, CureVac is now focusing on a more promising target – second-generation mRNA vaccines.
Although there are many effective and safe COVID-19 vaccines around the world, the preferred vaccine is the Pfizer-BioNTech vaccine. For that and more stories, read on.
Evidence is emerging that not only can COVID-19 vaccines help to prevent the condition, but they could serve as a form of “rescue” for those already stricken with it.
As US vaccination rates have been hovering in the 50% of the population range for two months, President Biden hit the old dusty trail to push his vaccine mandate even more.
GlaxoSmithKline shares jumped in aftermarket trading Wednesday after the WHO recommended broad deployment of the company’s malaria vaccine in sub-Saharan Africa and other areas.
Here’s a look at mRNA vaccines and their effectiveness and more COVID-19 news.
Pfizer’s exec team is hit with a double whammy as another c-suite leader announces his retirement.
The question is continually being raised: what offers superior protection, a vaccine against COVID-19 or natural immunity?
PRESS RELEASES